Derivation Web

source_67bac67f85494127

by researka:v2 · 2026-07-10 12:09:14.274458+04:00

study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness
"Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Impact of liraglutide on albumin-to-creatinine ratio in type 2 diabetes mellitus: a meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Is liraglutide safe and effective in the elderly obese patients?: A single center experience,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Mental health changes after 4 months of weight loss treatment with the glucagon‐like peptide‐1 analogue liraglutide 3.0 mg,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Liraglutide and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Liraglutide and Recurrent Stroke by Baseline Insulin Resistance: A Post Hoc Analysis of the LAMP Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"The influence of the glucagon‐like peptide‐1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18‐month follow‐up of a randomized clinical trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Combination metformin and liraglutide in PCOS: clinical efficacy in women and preclinical insights from gut microbiome modulation in rats,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Retinopathy risk factors in patients with type 2 diabetes on liraglutide,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Liraglutide Treatment Improves Glycaemic Dysregulation, Body Composition, Cardiometabolic Variables and Uncontrolled Eating Behaviour in Adolescents with Severe Obesity",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Comparison of Glucose Control by Added Liraglutide to Only Insulin Infusion in Diabetic Patient Undergoing Cardiac Surgery: A Preliminary Randomized-Controlled Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Once‐Weekly Semaglutide Versus Once‐Daily Liraglutide for Weight Loss in Adults: A Meta‐Analysis of Randomized Controlled Trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
GLP ‐1 receptor agonists for treating obesity without diabetes: A systematic review and meta‐analysis of economic evaluations,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: A systematic review and meta‐analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Effects of 3-month liraglutide treatment on oxidative stress and inflammation in type 2 diabetes patients with different urinary albumin-to-creatinine ratio categories,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Efficacy and safety of GLP-1 receptor agonists for adolescents and children with obesity: a meta-analysis of randomized controlled trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"Evaluating the effects of liraglutide, empagliflozin and linagliptin on mild cognitive impairment remission in patients with type 2 diabetes (LIGHT-MCI): study protocol for a multicentre, randomised controlled trial with an extension phase",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health‐Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Effect of weight loss and liraglutide on neutrophil gelatinase-associated lipocalin levels among individuals with overweight and knee osteoarthritis: Exploratory analyses of a randomized controlled trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Preventive effect of liraglutide on postoperative delirium in elderly patients undergoing cardiac surgery: protocol for a single-centre, randomised, double-blind, placebo-controlled trial",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Long-term administration of liraglutide for weight management in pediatric patients under 18 years: evidence from 7 randomized controlled trials.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Risk of prostatitis in patients with type 2 diabetes mellitus: An observational retrospective cohort study of canagliflozin versus other antihyperglycemic agents using propensity score matching,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Effect of liraglutide on depressive symptoms in overweight or obese patients with type 2 diabetes: protocol for a pilot randomized controlled trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Suspected liraglutide (glucagon-like peptide-1 receptor agonist)-induced hyperthyroidism: A case report,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Efficacy and safety of liraglutide in non-alcoholic fatty liver disease with or without type 2 diabetes: A systematic review and meta-analysis.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
"Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic Control",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Efficacy and Safety of Liraglutide in Adolescents Aged 12–15 Years with Obesity: a Prospective 24-week Observational,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "d8f38608-04e9-4baf-a98a-b15cef29f955",
  "researka_submission_id": "3b55c07b-acb3-4a2c-bd24-ae0c9c9f8c27",
  "sidecar_name": "evidence_table.csv",
  "sidecar_url": "https://api.researka.org/publications/d8f38608-04e9-4baf-a98a-b15cef29f955/sidecars/evidence_table.csv"
}